Screener
Corvus Pharmaceuticals CRVS EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Corvus Pharmaceuticals’s reported figures.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
FAQ
- What is Corvus Pharmaceuticals's EBITDA?
- Corvus Pharmaceuticals (CRVS) reported EBITDA of -$14.85M in Q1 2026.
- How has Corvus Pharmaceuticals's EBITDA changed year-over-year?
- Corvus Pharmaceuticals's EBITDA decreased by 50.0% year-over-year, from -$9.9M to -$14.85M.
- What is the long-term trend for Corvus Pharmaceuticals's EBITDA?
- Over 4 years (2021 to 2025), Corvus Pharmaceuticals's EBITDA has grown at a 2.9% compound annual growth rate (CAGR), from -$38.17M to -$42.87M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Corvus Pharmaceuticals's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude